Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity

NCT05111912 is registered in ClinicalTrials.gov with Sciwind Biosciences APAC CO Pty. Ltd. as lead sponsor.

NCT NCT05111912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity
Lead sponsor
Sciwind Biosciences APAC CO Pty. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2021
Completion date
December 20, 2022
Enrollment
206 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity